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Purpose
The epidemiology of B-cell non-Hodgkin lymphoma (BNHL) in Asia is not well described, and 
rates of second primary malignancies (SPM) in these patients are not known. We aimed to 
describe temporal changes in BNHL epidemiology and SPM incidence in Korea.
Materials and Methods
A retrospective cohort study used claims data from the National Health Insurance Service 
that provides universal healthcare coverage in Korea. Newly diagnosed patients aged at 
least 19 years with a confirmed diagnosis of one of six BNHL subtypes (diffuse large cell 
B-cell lymphoma [DLBCL], small lymphocytic and chronic lymphocytic [CLL/SLL], follicular 
lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and lym-
phoplasmacytic lymphoma/Waldenström’s macroglobulinemia [WM]) during the period 
2006-2015 were enrolled and followed up until death, dis-enrolment, or study end, which-
ever occurred first. Patients with pre-existing primary cancers prior to the diagnosis of BNHL 
were excluded.    
Results
A total of 19,500 patients with newly diagnosed BNHL were identified out of 27,866 with 
non-Hodgkin lymphoma (NHL). DLBCL was the most frequently diagnosed subtype (41.9%-
48.4% of NHL patients annually, 2011-2015). Standardized incidence of the six subtypes 
studied per 100,000 population increased from 5.74 in 2011 to 6.96 in 2015, with most 
increases in DLBCL, FL, and MZL. The incidence (95% confidence interval) of SPM per 100 
person-years was 2.74 (2.26-3.29) for CLL/SLL, 2.43 (1.57-3.58) for MCL, 2.41 (2.10-2.76) 
for MZL, 2.23 (2.07-2.40) for DLBCL, 1.97 (1.61-2.38) for FL, and 1.41 (0.69-2.59) for WM. 
Conclusion
BNHL has been increasingly diagnosed in Korea. High rates of SPM highlight the need for 
continued close monitoring to ensure early diagnosis and treatment.  
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Introduction
B-cell non-Hodgkin lymphoma (BNHL) comprises a heter-
ogeneous group of lymphoid malignancies that differ in their 
clinical presentation and progression [1]. The most common 
type of mature BNHL in adults is diffuse large B-cell lympho-
ma (DLBCL), which comprises approximately 46% of mature 
BNHL in Korea [2]. Other subtypes include follicular lym-
phoma (FL), mantle cell lymphoma (MCL), marginal zone 
lymphoma (MZL, including mucosa-associated lymphoid tis-
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sue [MALT] lymphoma), chronic lymphocytic and small lym-
phocytic lymphoma (CLL/SLL), and Waldenström’s macro- 
globulinemia (WM or lymphoplasmacytic lymphoma). BNHL 
subtypes vary in their ethnic and regional distribution, pos-
sibly influenced by genetic, lifestyle, and environmental fac-
tors [1,3]. 
The prognosis of BNHL has improved in the last decade, 
attributed primarily to the addition of rituximab to standard 
chemotherapy regimens [4]. Depending on subtype, some 
patients will be cured with treatment and others will survive 
for longer than a decade [1]. Prolonged survival is associated 
with its own complications, such as the development of sec-
ond primary malignancies (SPM). A meta-analysis of 23 stud-
ies reported that SPM occur in patients with non-Hodg-kin’s 
lymphoma significantly more frequently than primary malig-
nancies in the general population, with a relative risk esti-
mated at 1.88 (95% confidence interval [CI], 1.58 to 2.22) [5]. 
However, most of the data came from North American and 
European populations, and only two Japanese studies were 
included from the Asian region. Exposure to chemotherapy, 
autologous stem cell transplant, total body irradiation, and 
younger age at diagnosis have all been implicated as risk fac-
tors in the development of SPM [5,6]. 
The incidence of BNHL is reportedly lower in Asian than in 
Western countries and the distribution of BNHL subtypes is 
also different [1,2]. Compared to Western countries, a higher 
proportion of patients in Asia with BNHL have MZL, and 
lower proportions have FL and CLL/SLL [7-9]. Some of these 
differences likely reflect known variations in genetic suscep-
tibility to BNHL between Asian and Western populations 
[10,11]. However, for some subtypes, other mechanisms, such 
as different molecular pathways or etiologic factors are thought 
to contribute to regional differences in incidence rates. For 
example, while the incidence of FL is lower in Asian than in 
Western populations, the occurrence of the characteristic bcl-2 
translocation found in FL is similar in healthy populations in 
both regions, suggesting that the development of FL may be 
triggered differently in Asia than in Western countries [12]. 
The Republic of Korea is a high-income, industrialized 
country that lies to the East of the Asian mainland, with a 
population of approximately 52 million. The Korean gov-
ernment began national health insurance programs in 1976, 
expanded their coverage to all citizens in 1989, and created a 
single-payer system (Korean National Health Insurance Sys-
tem, NHIS) from 2000 [13]. Those insured pay contributions 
and receive medical services from their healthcare providers. 
The National Health Information Database (NHID) is main-
tained by the NHIS and contains all medical and prescription 
drug claim records for the Korean population, and is a rich 
repository of information for health research [14]. 
Between 1999 and 2012, the age-standardized incidence 
of mature BNHL increased annually by 5.6% [2]. The rate of 
SPM among patients with BNHL in Korea is not known. To 
address this knowledge gap, we conducted a retrospective 
cohort study using claims data from the NHID to describe 
temporal changes in the incidence and prevalence of BNHL 
in Korea up until 2015, and to evaluate the incidence of SPM 




The NHID holds comprehensive information on health 
care utilization, demographic characteristics, and mortality 
for the whole population of South Korea [13,14]. The NHID 
was built in 2012 to perform NHIS activities using informa-
tion from medical treatment and health screening records, 
and socio-demographic data from an existing database sys-
tem [14]. Inpatient and outpatient visits including diagno-
ses recorded in International Classification of Diseases, 10th 
revision (ICD-10) format, length of stay, treatment costs, pro-
cedures, and prescriptions are recorded [13,14].  
2. Study population 
All patients who were newly diagnosed with one of six 
BNHL subtypes (ICD-10 codes C83.3 DLBCL, C91.1 CLL/ 
SLL, C82 FL, C83.1 MCL, C88.4 MALT lymphoma and C83.0 
MZL, or C88.0 WM) between 01 January 2006 and 31 Decem-
ber 2015 were identified in the NHID. Nodal and extra-nodal 
MZL were included under one category because they are 
unable to be differentiated under C83.0. Patients were defined 
as newly diagnosed if they had no previous record of diagno-
sis or treatment of BNHL for at least 1 year. The diagnosis of 
BNHL was confirmed if the patient had at least three outpa-
tient visits, and/or one hospital admission with the specific 
ICD-10 code after the diagnosis index date. 
Patients were included in the study cohort if they were at 
least 19 years of age and if they had been in the database for 
at least 12 months prior to the BNHL diagnosis index date. 
Patients were excluded if they had any cancer other than 
BNHL prior to the diagnosis index date. 
SPM were defined as new malignant tumors diagnosed 
more than 180 days after the BNHL index date to reduce the 
risk of including pre-existing undiagnosed malignancies in 
the analysis [15], SPM were identified in the NHID. Patients 
were followed up for SPM from the diagnosis index date until 
death, end of the study period, or dis-enrolment, whichever 
occurred first. All kinds of solid tumors were considered as 
SPM. For hematologic malignancies as SPM, we included acute 
myeloid leukemia (C92), monocytic leukemia (C93), mye-
lodysplastic syndrome (D46), and myeloproliferative neo- 
plasms (D47), but excluded acute leukemia of unspecified 
cell type (C95), multiple myeloma (C90) and all subtypes of 
lymphoma. 
Since there have been changes in the diagnostic codes for 
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BNHL subtypes in the NHIS over time, the study period was 
divided into two parts: years 2006 to 2010 and years 2011 to 
2015. The cohort analysis of incidence and prevalence was 
conducted using data from 2011-2015, whereas the full data-
set from 2006 to 2015 was used to estimate the incidence of 
SPM.
3. Statistical analysis
The incidence of BNHL for each study year was calculat-
ed as the number of newly diagnosed patients with BNHL 
divided by the total Korean population in each calendar year. 
Prevalence included all patients with existing and incident 
BNHL divided by the total Korean population in each calen-
dar year. Mortality rates for BNHL and its six subtypes were 
calculated as the number of patient deaths due to any cause 
divided by the total Korean population in each calendar year. 
Age-standardized rates were calculated by the direct stand-
ardization method, using the age distribution of the Korean 
population in 2011 as the standard population. Overall sur-
vival (OS) was calculated using Kaplan-Meier methods. 
The number of patients with at least one SPM was deter-
mined and the incidence calculated using the number of 
patients divided by the sum of the total follow-up period 
(per 100 person-years). Kaplan-Meier survival curves for 
SPM used the first SPM event for the time-to-event analysis. 
Cochran-Armitage tests were used to describe trends in the 
data over time. All analyses were performed using SAS ver. 
9.4 (SAS Institute Inc., Cary, NC). 
4. Ethical statement
All personally identifiable information was encrypted to 
protect patient privacy. The study protocol was reviewed 
and received approval from the Institutional Review Board 
of Yonsei University Health System, Severance Hospital with 
a waiver of informed consent (4-2016-0824), and the National 
Health Information Data Request Review Committee of the 
NHIS (REQ0000006774).
Results
A total of 19,500 patients with BNHL in the NHID had a 
diagnosis index date between 2006 and 2015 out of 27,866 
with NHL (Table 1). Of these, 13,671 were diagnosed bet-
ween 2011-2015 and were included in the cohort analysis. 
The mean age of patients diagnosed between 2011 and 2015 
was 59.5 years, 60.0% (n=8,202) of patients were 19-64 years 
of age and 54.0% (n=7,389) were male. 
The total number of BNHL cases diagnosed increased 
annually from 2,298 in year 2011 up to 3,128 in year 2015. 
DLBCL was the most common diagnosis in each study year 
(Table 1), although the relative proportion of DLBCL tended 
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2011 to 43.4% in 2014 (but increasing to 48.4% in 2015). The 
proportion of CLL/SLL decreased during the study, from 
4.6% of NHL in 2011 to 3.7% in 2015. By contrast, the propor-
tion of FL and MZL increased between 2011 and 2015 (6.4% 
to 7.8% for FL and MZL 16.6% to 21.7% for MZL). There was 
little change in the proportion of patients diagnosed with 
NHL with MCL or WM over time.
1. Incidence, prevalence, and all-cause mortality rates in 
patients with BNHL
The age-standardized incidence of BNHL increased over 
time from 5.74 (95% CI, 5.51 to 5.98) per 100,000 population 
in 2011 to 6.96 (95% CI, 6.72 to 7.20) per 100,000 population in 
2015 (Table 2). Age-standardized incidence rates of DLBCL, 
MZL, and FL increased significantly (p < 0.001 for all), with 
similar increases observed in men and women (Fig. 1). Bet-
ween 2011 and 2015, the incidence of DLBCL increased by 
11%, the incidence of MZL increased by 32%, and the inci-
dence of FL increased by 25%. Age-standardized incidence 
rates of MCL and WM remained steady between 2011 and 
2015, although there was some annual variation in the inci-
dence in women versus men for WM. A decrease in the inci-
dence of CLL/SLL appeared in 2015 (Fig. 1). 
Crude and age-standardized BNHL prevalence increased 
steadily each year and were approximately 2.5-fold higher 
in 2015 than in 2011 (Table 2). Prevalence rates of each BNHL 
subtype also increased (Fig. 2). The age-adjusted prevalence 
of DLBCL increased by 1.8-fold, CLL/SLL by 1.7-fold, FL by 
2.6-fold, MCL by 4.0-fold, MZL by 11.3-fold and WM by 1.6-
fold (p < 0.001 for all six subtypes). Increases appeared to be 
similar in women and men for all BNHL subtypes.
Crude and age-standardized BNHL mortality rates increa-
sed over time. Age-standardized mortality increased by 42%, 
from 1.33 (95% CI, 1.22 to 1.44) per 100,000 population in 
2011 to 1.89 (95% CI, 1.76 to 2.02) per 100,000 population in 
2015 (Table 2). Age-standardized mortality increased among 
men and women for all BNHL subtypes; except for women 
with WM in whom the mortality rate remained rather con-
stant (Fig. 3). The increase in age-standardized mortality was 
statistically significant for DLBCL (p=0.010), and CLL/SLL, 
MCL, MZL (p < 0.001). Between 2011 and 2015, all-cause 
mortality rates increased by 35% in patients with for DLBCL, 
49% in patients with CLL/SLL, 31% in patients with FL, 
172% in MCL, 77% in MZL and 121% in WM. 
2. Overall survival 
Five-year OS was highest in patents with MZL (88%) fol-
lowed by FL (79%), CLL/SLL (62%), DLBCL (60%), WM 
(54%), and MCL (53%) (Table 3, Fig. 4). Up to three years 
after diagnosis, DLBCL patients had the lowest survival rate. 
However, when followed for a longer duration, MCL and 
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3. Occurrence of SPM 
Of the 19,500 patients diagnosed with BNHL in 2006-2015, 
1,183 patients (6.1%) developed a total of 1,203 SPMs. The 
incidence of the first SPM was highest in patients with CLL/
SLL (2.74 per 100 person-years), followed by MCL (2.43 per 
100 person-years), MZL (2.41 per 100 person-years), DLBCL 
(2.23 per 100 person-years), FL (1.97 per 100 person-years), 
and WM (1.41 per 100 person-years) (Table 4). 
The incidence of solid SPM was highest in patients with 
MCL (2.32 per 100 person-years) (Table 4). The most frequent 
solid malignancies were prostate cancer in 190 patients (0.64 
per 100 person-years; 95% CI, 0.55 to 0.73), liver cancer in 
234 patients (incidence rate 0.43 per 100 person-years; 95% 
CI, 0.38 to 0.49), stomach cancer in 174 patients (0.32 per 100 
person-years; 95% CI, 0.28 to 0.37), colorectal cancer in 167 
patients (0.31 per 100 person-years; 95% CI, 0.26 to 0.36), lung 
cancer in 139 patients (0.26 per 100 person-years; 95% CI, 
0.22 to 0.30), brain cancer in 88 patients (0.16 per 100 person-
Fig. 1.  Age-standardized incidence rates (95% confidence intervals) of B-cell non-Hodgkin lymphoma subtypes in South Korea, 2011-2015. 
Age-standardized rates were calculated by direct standardization method, using the 2011 Korean population as the reference. p-values for 
trend: DLBCL p < 0.001 (A), MZL p < 0.001 (B), CLL/SLL p=0.489 (C), MCL p=0.077 (D), FL p < 0.001 (E), WM p=0.661 (F). DLBCL, diffuse 
large B-cell lymphoma; MZL, marginal zone lymphoma; CLL/SLL, small lymphocytic lymphoma and chronic lymphocytic; MCL, mantle 

















































































































































































1266     CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2020;52(4):1262-1272
years; 95% CI, 0.13 to 0.20), pancreatic cancer in 84 patients 
(0.15 per 100 person-years; 95% CI, 0.12 to 0.19), ovarian can-
cer in 37 patients (0.15 per 100 person-years; 95% CI, 0.11 to 
0.21), breast cancer in 33 patients (0.13 per 100 person-years; 
95% CI, 0.09 to 0.19), and head and neck cancer in 59 patients 
(0.11 per 100 person-years; 95% CI, 0.08 to 0.14).The cumula-
tive incidence at 5 years for developing the first SPM was 
15% for CLL/SLL, 12% for MCL and MZL, 11% for DLBCL, 
9% for FL, and 7% for WM (Table 5). 
A sensitivity analysis conducted in which the SPM analysis 
was restricted to 2011-2015 after implementation of changes 
in the diagnostic codes for BNHL subtypes showed similar 
results compared to the entire study period from 2006-2015 
(data not shown).
 
Fig. 2.  Age-standardized prevalence (95% confidence intervals) of B-cell non-Hodgkin lymphoma subtypes in South Korea, 2011-2015. 
Age-standardized rates were calculated by direct standardization method, using the 2011 Korean population as the reference. p-values 
for trend: DLBCL p < 0.001 (A), MZL p < 0.001 (B), CLL/SLL p < 0.001 (C), MCL p < 0.001 (D), FL p < 0.001 (E), WM p < 0.001 (F). DLBCL, 
diffuse large B-cell lymphoma; MZL, marginal zone lymphoma; CLL/SLL, small lymphocytic lymphoma and chronic lymphocytic; MCL, 
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Discussion
To our knowledge, this is the first analysis of the incidence 
of SPM in Korean patients with BNHL. By analyzing virtu-
ally all cases of BNHL in the Korean health system, we found 
a high rate of progression to SPM, with a 5-year cumula-
tive incidence of 7% to 15% depending on subtype after the 
BNHL diagnosis, and evidence of progression to SPM that 
continued past the 9-year follow-up period of our study. This 
contrasts with 5-year cumulative incidence of approximately 
3% for patients with early stage Hodgkin’s lymphoma [16], 
and 6% for patients with multiple myeloma [17]. 
Our estimates of the cumulative incidence of SPM are 
somewhat higher than reported elsewhere. Studies in the 
United States using the Surveillance, Epidemiology, and End 
Results (SEER) database report 5- and 10-year cumulative 
Fig. 3.  Age-standardized all-cause mortality rates (95% confidence intervals) in patients with B-cell non-Hodgkin lymphoma subtypes 
in the Korean population, 2011-2015. Age-standardized rates were calculated by direct standardization method, using the 2011 Korean 
population as the reference. p-values for trend: DLBCL p < 0.010 (A), MZL p < 0.001 (B), CLL/SLL p < 0.001 (C), MCL p < 0.001 (D), FL 
p=0.937 (E), WM p=0.923 (F). DLBCL, diffuse large B-cell lymphoma; MZL, marginal zone lymphoma; CLL/SLL, small lymphocytic 
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incidence of SPM of 5.68% and 11.06%, respectively for 
patients with FL, and 9.5% and 16.1% for patients with WM 
[18,19]. Another SEER study reported that 8.2% of patients 
with MCL developed a SPM, although the median follow-
up was only 31 months [20]. The 5- and 10-year cumulative 
incidences of SPM in patients with DLBCL was 5.41% and 
10.47% in California in the post-rituximab era, which was 
higher than in the years prior to rituximab introduction [21]. 
At this time, we have no clear view of why SPM may be more 
frequent in Korean patients with BNHL than elsewhere, 
although different follow-up periods, study populations, 
methodologies and possibly treatment regimens are likely 
to have contributed. Similar data on SPM rates in patients 
with BNHL from Asian countries are limited, and we can-
not confirm whether the rates of SPM observed in our study 
are reflective of trends present across Asia. Corroborative 
data from other parts of Asia as well as studies investigat-
ing the genetic predispositions associated with BNHL in Asia 
populations could help inform these findings. In 2015 the 
age-standardized cancer incidence rate in Korea was 258.9 
per 100,000 population, and the lifetime cumulative risk of 
developing cancer was 35.3% [22]. However, the cumulative 
lifetime risk of cancer is expected to increase as because the 
average lifespan of Koreans continues to increase [23].   
Consistent with previous reports, the age-standardized 
incidence rate of BNHL in Korea was substantially lower 
than those observed in Western countries, although direct 
comparisons should be made cautiously given that the data 
were not standardized using the same reference population 
[2,24]. The incidence of DLBCL was an exception. In Europe, 
the age-standardized incidence of DLBCL in 2000-2002 was 
3.13 per 100,000, which is lower than our 2015 estimate of 3.67 
























































































































































































































































































































































































































































































































Fig. 4.  Overall survival after B-cell non-Hodgkin lymphoma  
diagnosis index date: follow-up of all patients enrolled from 
2006-2015 and death from any cause. MZL, marginal zone lym-
phoma; FL, follicular lymphoma; DLBCL, diffuse large B-cell 
lymphoma; CLL/SLL, small lymphocytic lymphoma and chron-
ic lymphocytic; MCL, mantle cell lymphoma; WM, Walden-
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Korea [24]. The European age-standardized incidence was 
3.79 per 100,000 for CLL/SLL, and 1.92 per 100,000 for FL, 
compared with 2015 estimates of 0.27 and 0.63 per 100,000 
respectively in Korea. In Canada, the incidence of mature 
BNHL was 54.0 per 100,000 population in men, and 38.5 per 
100,000 in women between 2010-2013 [25], compared to an 
overall rate of < 7 per 100,000 population during the same 
years in Korea. 
The age-adjusted incidence of BNHL increased by 17% 
from 2011 to 2015. The increase in incidence was driven by 
changes in DLBCL, MZL, and FL, which increased by 17%, 
40%, and 36%, respectively, over the study period. In paral-
lel, there was a 16% decrease in the incidence of CLL/SLL. 
The changes in disease incidence appeared to be similar in 
men and women. Our observations compliment and extend 
those reported by Lee et al. [2] using data from the Korean 
Central Cancer Registry and confirm the steady increase in 
the age-standardized incidence of DLBCL, MZL, and FL in 
Korea over the last 16 years (Fig. 5). While we cannot exclude 
that some of the observed increases may be due to improved 
surveillance or diagnostic methods, marked increases in the 
incidence of DLBCL and FL have been observed previously 
in other countries including Canada and the United States 
[25,26]. Age-standardized mortality rates in patients with 
BNHL increased in the Korean population over the study 
period reflecting increases in incidence and prevalence. 
The distribution of BNHL subtypes in our study was some-
what different to that reported previously by Yoon et al. [8] 
from a single large institution in Korea using data from 1989 
to 2008. Compared to Yoon et al. [8], we observed higher pro-
portions of patients with CLL/SLL (4.4% to 6.2% vs. 3.7%), 
FL (8.1% to 9.8% vs. 3.4%) and WM (0.9% to 1.3% vs. 0.5%). 
Estimates for the other subtypes were within the same range. 
Differences for some subtypes could reflect the case defini-
tion used by Yoon et al. [8] which was laboratory-based with 
exclusion of patients without pathological material available 
for review, in contrast to our study that used ICD-10 codes 
arising from claims data. Additionally, our study covered a 
later period, from 2006 to 2015, allowing us to include more 
patients from recent years.
Lee et al. [2], explored the epidemiology of lymphoid 
malignancies in Korea using data from the Korean Central 
Cancer Registry between 1999 and 2012. The age-standard-
ized incidence rate of mature BNHL increased significantly 
(5.6% annually) during the study and was 6.60 per 100,000 in 
2012. Significant increases were also observed for MCL (7.1% 
annual increase), FL (5.1% annual increase), DLBCL (4.0% 
annual increase), and MZL (18.4% annual increase). 
Strengths of our study include the use of a national health 
insurance database which ensured we captured essentially 
all cases of BNHL and SPMs diagnosed in Korea during the 
study years. The 10-year study duration was important for 
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diagnosis and the development of SPM. Median latency 
periods from diagnosis until the development of SPM are 
approximately 4 years [18,20]. 
Potential study limitations included the lower accuracy of 
coding information in the years 2006-2010, which meant that 
we restricted the cohort analysis of incidence and prevalence 
to 5 years from 2011. In addition, patients who achieved a 
cure after appropriate treatment might be included in the cal-
culation of prevalence in this study because we were not able 
to identify the exact disease status. Therefore, prevalence 
might be overestimated. The Korean health insurance data-
base does not differentiate between malignancies that are 
primary or metastatic. By excluding patients with a previ-
ous cancer diagnosis, solid tumors diagnosed more than 180 
days after the BNHL index date were likely to be SPM. For 
hematological malignancies it was not possible to distinguish 
between disease progression/transformation and a new pri-
mary hematological cancer. We excluded unspecified acute 
leukemia, multiple myeloma, and all subtypes of lymphoma 
to reduce the risk of over-estimating hematological SPM. 
However, potential overestimation of the incidence of SPM 
cannot be ruled out. Nevertheless, in view of the different 
epidemiology of BNHL in Asia compared to Western coun-
tries, our findings potentially reflect an important trend of 
increased SPM in Asia that warrants further investigation. 
In conclusion, the incidence of BNHL in Korea continues to 
increase, driven by increases in MZL, FL, as well as DLBCL. 
Our findings present new challenges for clinicians managing 
BNHL. High incidences of SPM in patients with BNHL war-
rant careful ongoing review of these patients to ensure early 
diagnosis and treatment. BNHL and the long-term compli-
cations associated with survival remain important unmet 
medical needs in South Korea.
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